DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

DongKoo Bio & Pharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	23,232	25,372	15,713	12,514	19,557	4,881
Short-Term Investments	506.9	506.9	1,941	1,351	143.14	87.57
Trading Asset Securities	15,912	10,371	5,245	21,271	12,399	24,616
Cash & Short-Term Investments	39,651	36,250	22,898	35,136	32,100	29,585
Cash Growth	102.38%	58.31%	-34.83%	9.46%	8.50%	168.63%
Accounts Receivable	21,079	19,876	19,879	18,503	15,774	17,455
Other Receivables	388.6	1,352	1,570	898.47	633.49	136.73
Receivables	24,247	23,953	22,449	19,402	16,408	17,592
Inventory	51,293	45,962	42,606	31,428	24,964	24,971
Prepaid Expenses	558.14	324.71	216.61	225.89	229.66	200.1
Other Current Assets	583.31	751.62	195.02	1,226	131.5	4.72
Total Current Assets	116,332	107,242	88,365	87,417	73,832	72,353
Property, Plant & Equipment	66,654	66,222	50,483	39,681	40,051	40,377
Long-Term Investments	50,883	50,419	39,800	33,619	35,498	26,495
Other Intangible Assets	13,274	13,172	10,903	9,010	3,048	2,081
Long-Term Accounts Receivable	-	-	-	-	-	16.66
Long-Term Deferred Tax Assets	3,919	3,162	291.5	6.95	-	-
Other Long-Term Assets	3,151	3,843	1,260	2,325	2,358	3,031
Total Assets	254,214	244,061	191,103	172,059	154,786	144,353
Accounts Payable	18,003	15,591	11,202	14,300	11,591	9,191
Accrued Expenses	10,623	11,337	10,274	9,637	6,496	4,683
Short-Term Debt	74,406	74,876	40,500	33,000	18,070	18,000
Current Portion of Long-Term Debt	1,313	-	-	-	5,000	-
Current Portion of Leases	658.99	681.03	842.63	567.83	453.23	523.99
Current Income Taxes Payable	2,638	3,325	1,638	2,576	1,978	915.59
Other Current Liabilities	11,007	9,441	8,863	5,963	6,434	7,194
Total Current Liabilities	118,649	115,251	73,318	66,044	50,022	40,508
Long-Term Debt	19,529	10,467	1,447	-	-	5,000
Long-Term Leases	512.38	616.95	1,014	754.22	770.27	219.01
Long-Term Deferred Tax Liabilities	8.89	8.89	4.5	140.93	2,315	3,034
Other Long-Term Liabilities	13,519	12,269	4,596	3,015	1,350	939.53
Total Liabilities	152,247	138,613	80,658	69,953	54,662	49,701
Common Stock	14,232	14,232	14,232	14,232	14,232	4,802
Additional Paid-In Capital	33,562	33,063	33,063	33,063	33,063	42,569
Retained Earnings	63,394	67,320	69,735	61,675	57,158	49,727
Treasury Stock	-10,545	-10,545	-7,137	-7,058	-4,062	-2,065
Comprehensive Income & Other	1,279	1,261	507.18	193.39	-266.18	-380.89
Total Common Equity	101,923	105,332	110,400	102,106	100,124	94,653
Minority Interest	43.9	116.03	44.92	-	-	-
Shareholders' Equity	101,967	105,448	110,445	102,106	100,124	94,653
Total Liabilities & Equity	254,214	244,061	191,103	172,059	154,786	144,353
Total Debt	96,418	86,641	43,804	34,322	24,294	23,743
Net Cash (Debt)	-56,768	-50,391	-20,906	813.88	7,806	5,842
Net Cash Growth	-	-	-	-89.57%	33.61%	-
Net Cash Per Share	-2089.07	-1845.19	-756.89	29.32	276.23	206.49
Filing Date Shares Outstanding	27.04	27.04	27.61	27.62	28.04	28.29
Total Common Shares Outstanding	27.04	27.04	27.61	27.62	28.04	28.29
Working Capital	-2,317	-8,009	15,046	21,374	23,811	31,844
Book Value Per Share	3769.04	3895.10	3998.84	3696.33	3570.78	3345.63
Tangible Book Value	88,649	92,160	99,497	93,096	97,076	92,572
Tangible Book Value Per Share	3278.18	3408.02	3603.92	3370.16	3462.08	3272.08
Land	13,262	13,262	10,849	10,849	10,584	10,584
Buildings	28,216	39,356	29,667	27,353	26,899	26,120
Machinery	12,075	30,310	19,768	17,741	17,813	16,838
Construction In Progress	8,091	7,823	10,694	1,451	887.9	844.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.